Dr. Baxter was the first to elucidate the x-ray crystallographic structure of a liganded nuclear receptor domain. This discovery has greatly enhanced our understanding of how drugs interact with these receptors and provides insight into how to develop improved pharmaceuticals. Bionovo's drug candidates, like 20% of pharmaceuticals, act through nuclear receptors.
John was also first to discover a receptor defect (for any hormone) causing hormone resistance. This discovery is critical to understanding of many diseases such as diabetes and breast cancer. In collaboration with Bristol Myers-Squibb and Karo- Bio A.B. he has helped to develop drugs now being tested for treatment of obesity, diabetes and atherosclerosis.
Dr. Baxter is a member of the National Academy of Sciences. He is the past President of the Endocrine Society. He was Chief of the Division of Endocrinology and Director of Metabolic Research Unit at the University of California, San Francisco. He was a founder and director of Scios/Nova, Karo-Bio A.B. (Stockholm), Calhoun Vision,, and SciClone Pharmaceuticals (SCLN). He is the largest shareholder, Director, and member of the Executive Committee for One Touch Technologies. After completing an undergraduate degree in Chemistry from the University of Kentucky, John received his medical degree from Yale University. Dr. Baxter is currently: Senior Member, Co-Director of the Diabetes Center, and Director of the Genomics Core of the Methodist Hospital Research Institute, and Chief of Endocrinology, the Department of Medicine, The Methodist Hospital, Houston TX.
Bionovo is a pharmaceutical company focused on the discovery and
development of safe and effective treatments for women's health and cancer,
markets with significant unmet needs and billions in potential annual
revenue. The company applies its expertise in the biology of menopause and
cancer to design new drugs derived from botanical sources which have novel
|SOURCE Bionovo Inc.|
Copyright©2008 PR Newswire.
All rights reserved